Combined Endocardial and Epicardial Catheter Ablation in Arrhythmogenic Right Ventricular Dysplasia Incorporating Scar Dechanneling Technique
Arrhythmia Section, Cardiology Department, Thorax Institute, Hospital Clínic and IDIBAPS, Barcelona, Catalonia, Spain. Circulation Arrhythmia and Electrophysiology
(Impact Factor: 4.51).
12/2011; 5(1):111-21. DOI: 10.1161/CIRCEP.110.960740
Ventricular tachycardia (VT) ablation in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) has a low success rate. A more extensive epicardial (Epi) arrhythmogenic substrate could explain the low efficacy. We report the results of combined endocardial (Endo) and Epi VT ablation and conducting channel (CC) elimination.
Eleven consecutive patients with ARVD/C were included in the study. A high-density 3D Endo (321±93 sites mapped) and Epi (302±158 sites mapped) electroanatomical voltage map was obtained during sinus rhythm to define scar areas (<1.5 mV) and CCs inside the scars, between scars, or between the tricuspid annulus and a scar. The end point of the ablation procedure was the elimination of all identified CCs (scar dechanneling) and the abolition of all inducible VTs. The mean procedure and fluoroscopy time were 177±63 minutes and 20±8 minutes, respectively. Epi scar area was larger in all cases (26±18 versus 94±45 cm(2), P<0.01). The combined Endo and Epi VT ablation eliminated all clinical and induced VTs, and the addition of scar dechanneling resulted in noninducibility in all cases. Seven patients continued on sotalol. During a median follow-up of 11 months (6-24 months), only 1 (9%) patient had a VT recurrence. There was a single major bleeding event that did not preclude a successful procedure.
Combined Endo and Epi mapping reveals a wider Epi VT substrate in patients with ARVD/C with clinical VTs. As a first-line therapy, combined Endo and Epi VT ablation incorporating scar dechanneling achieves a very good short- and midterm success rate.
Available from: Andreas Müssigbrodt
- "Seven patients (64%) received sotalol after catheter ablation procedure. During a median follow-up of 11 months (6–24 months), only 1 (9%) patient had a VT recurrence . "
[Show abstract] [Hide abstract]
ABSTRACT: Radiofrequency catheter ablation is currently considered as the therapeutic option of choice in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) and recurrent ventricular tachycardia (VT).
This study intended to assess the long-term outcome of catheter ablation in patients with ARVC and electrical storm. The specific objective was to assess the relationship between precordial QRS amplitude ratio and outcome of catheter ablation in these patients.
Twenty-eight patients (19 men, age 52.3±14.2years) underwent 48 catheter ablation procedures (range 1-6, six epicardial). During a mean follow-up of 18.7±15.1months, 13 patients (46.5%) experienced VT recurrence. Age >50years and ∑QRSmvV1-V3/∑QRSmvV1-V6≤0.48 but not right ventricular size and acute ablation outcome were associated with VT recurrence during the follow up.
Age >50years and ∑QRSmvV1-V3/∑QRSmvV1-V6≤0.48 predict recurrence of VT after successful radiofrequency catheter ablation of VT in patients with ARVC and electrical storm.
Copyright © 2014 Elsevier Inc. All rights reserved.
Journal of Electrocardiology 11/2014; 48(1). DOI:10.1016/j.jelectrocard.2014.10.013 · 1.36 Impact Factor
Circulation 03/2012; 125(11):e466-8. DOI:10.1161/CIRCULATIONAHA.111.087858 · 14.43 Impact Factor
Circulation 10/2012; 126(14):1752-69. DOI:10.1161/CIRCULATIONAHA.111.060327 · 14.43 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.